Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Income from Continuing Operations (2016 - 2025)

Bioadaptives' Income from Continuing Operations history spans 7 years, with the latest figure at 823346.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 121.46% to 823346.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 1619557.0, a 148.01% decrease, with the full-year FY2025 number at 1557898.0, down 73.26% from a year prior.
  • Income from Continuing Operations hit 823346.0 in Q4 2025 for Bioadaptives, down from 379502.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for BDPT hit a ceiling of 19095.0 in Q4 2023 and a floor of 823346.0 in Q4 2025.
  • Historically, Income from Continuing Operations has averaged 223249.4 across 5 years, with a median of 177084.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: soared 106.86% in 2023 and later tumbled 2047.04% in 2024.
  • Tracing BDPT's Income from Continuing Operations over 5 years: stood at 89602.0 in 2021, then tumbled by 210.84% to 278520.0 in 2022, then soared by 106.86% to 19095.0 in 2023, then tumbled by 2047.04% to 371788.0 in 2024, then tumbled by 121.46% to 823346.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BDPT at 823346.0 in Q4 2025, 379502.0 in Q3 2025, and 157914.0 in Q2 2025.